Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Janet Wittes

Showing results (81-90 of 122) with videos related to

Pageof 13
Sort By:
The American Journal of Tropical Medicine and Hygiene|May 14, 2005
A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosumLaarni G Villahermosa, Tranquilino T Fajardo, Rodolfo M Abalos, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of colorectal adenomatous polypsNadir Arber, Craig J Eagle, Julius Spicak, et al.
The Journal of Urology|March 3, 2009
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2009
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
JAMA|April 24, 2003
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black, William J Elliott, Gregory Grandits, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
The Journal of Pediatrics|May 2, 2006
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Roberto Giugliani, Ida Schwartz, et al.
Journal of Hypertension|April 19, 2005
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical regionHenry R Black, William J Elliott, Gregory Grandits, et al.
Pageof 13

Showing results (81-90 of 122) with videos related to

Sort By:
Pageof 13
The American Journal of Tropical Medicine and Hygiene|May 14, 2005
A randomized, double-blind, double-dummy, controlled dose comparison of thalidomide for treatment of erythema nodosum leprosumLaarni G Villahermosa, Tranquilino T Fajardo, Rodolfo M Abalos, et al.
JACC. Heart Failure|March 26, 2024
Training the Next Generation of Data Monitoring Committee Members: An Initiative of the Heart Failure CollaboratoryThomas R Fleming, Janet Wittes, Mona Fiuzat, et al.
The New England Journal of Medicine|September 1, 2006
Celecoxib for the prevention of colorectal adenomatous polypsNadir Arber, Craig J Eagle, Julius Spicak, et al.
The Journal of Urology|March 3, 2009
Use of 5alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2009
Use of 5-alpha-reductase inhibitors for prostate cancer chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice GuidelineBarnett S Kramer, Karen L Hagerty, Stewart Justman, et al.
International Journal of Cardiology|May 4, 2016
New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approvalFaiez Zannad, Patrick Rossignol, Wendy Gattis Stough, et al.
JAMA|April 24, 2003
Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trialHenry R Black, William J Elliott, Gregory Grandits, et al.
Circulation|April 2, 2008
Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysisScott D Solomon, Janet Wittes, Peter V Finn, et al.
The Journal of Pediatrics|May 2, 2006
Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension studyPaul Harmatz, Roberto Giugliani, Ida Schwartz, et al.
Journal of Hypertension|April 19, 2005
Results of the Controlled ONset Verapamil INvestigation of Cardiovascular Endpoints (CONVINCE) trial by geographical regionHenry R Black, William J Elliott, Gregory Grandits, et al.
Pageof 13